Muscle-invasive Bladder Cancer Therapeutics Market

Muscle-invasive Bladder Cancer Therapeutics Market Outlook (2023 to 2033)

The global muscle-invasive bladder cancer therapeutics market expanded at a CAGR of 10.8% from 2012 to 2022 and reached a value of US$ 889.5 million in 2022. The market is predicted to surge ahead at a CAGR of 15.8% and end up at US$ 4.99 billion by 2033.

• According to Persistence Market Research, low-grade bladder cancer therapeutics dominated the global market with a contribution of US$ 620.7 million in 2022.
• Muscle-invasive bladder cancer (MIBC) therapeutics accounted for 29.4% of the global bladder cancer therapeutics market in 2022.

One of the key factors influencing the growth of the market is the increasing incidence of bladder cancer across the world.

• According to the World Health Organization (WHO), every year, bladder cancer is diagnosed in more than 0.6 million people worldwide and more than 200,000 people die from this disease. As the incidence of bladder cancer continues to rise, the demand for effective treatment options for MIBC (muscle-invasive bladder cancer) is expected to increase.

Another potential driving factor is the availability of new and innovative treatments for MIBC. Recent advances in immunotherapy, targeted therapy, and chemotherapy have led to the development of several promising drugs for MIBC. For example, immunotherapy drugs such as pembrolizumab and atezolizumab have shown promising results in clinical trials and have been approved for the treatment of MIBC.

Increasing awareness and adoption of minimally invasive surgical techniques also influenced the market positively. Transurethral resection of bladder tumor (TURBT) is a common surgical procedure used to diagnose and treat MIBC. More advanced procedures such as robot-assisted radical cystectomy (RARC) and laparoscopic radical cystectomy (LRC) are gaining popularity due to their potential benefits, including reduced blood loss, shorter hospital stay, and faster recovery. This will ultimately boost market growth further in the future.

Growing aging population is expected to drive the demand for MIBC treatments. The risk of bladder cancer increases with age, and as the global population continues to age, the number of people diagnosed with MIBC is expected to increase, which will play a vital role in expanding the market as well.

The global market for muscle-invasive bladder cancer therapeutics is expected to grow due to several potential driving factors, including the increasing incidence of bladder cancer, availability of new and innovative treatments, adoption of minimally invasive surgical techniques, and a growing aging population.

What are the Factors Driving the Adoption of Muscle-invasive Bladder Cancer Therapies?

“Advanced Genomic Sequencing for Improved Identification of Mutations Driving Demand for Tailored MIBC Therapeutics”

Development of innovative therapies that target specific biomarkers or pathways involved in MIBC is driving the growth of the market.

Therapies that target PD-L1, FGFR3, or HER2/neu have shown promising results in clinical trials and could provide new treatment options for MIBC patients. This will provide potential growth prospects for manufacturers operating in the muscle-invasive bladder cancer therapeutics market.

Use of personalized medicine, where treatments are tailored to the genetic makeup of each patient, is another factor driving the market. Advances in genomic sequencing technology have made it possible to identify specific genetic mutations that drive the growth of MIBC tumors and targeted therapies can be developed to address these mutations.

Emerging markets in Asia Pacific and Latin America exhibit a high incidence of bladder cancer, and the market in these regions is expected to grow exponentially in the future. The increasing availability of healthcare infrastructure and the rising adoption of new treatment options are likely to drive growth in these regions.

Collaborations between industry players, such as pharmaceutical companies, diagnostic companies, and medical device manufacturers, could also drive exponential growth in the market. Partnerships and collaborations can help accelerate the development of new therapies and diagnostic tools and improve patient outcomes.

What Can Hurt the Popularity of Muscle-invasive Bladder Cancer Therapeutics?

“High Treatment Cost and Unfavorable Side Effects of Muscle-invasive Bladder Cancer Therapeutics”

The cost of treatment for muscle-invasive bladder cancer is high and can be a significant barrier for patients to opt for the treatment. This may limit the growth of the market as patients may not be able to afford the treatment, particularly in developing economies where there is a lack of access to healthcare services as well as low to moderate healthcare spending.

There are limited treatment options available for muscle-invasive bladder cancer, especially in underserved and developing countries. This is because patients may not have access to effective treatments and may opt for alternative treatments or decide not to undergo treatment at all, which can significantly affect the growth of the market.

Lack of awareness about muscle-invasive bladder cancer among patients and healthcare providers can limit the growth of the market. This is because patients may not seek timely treatment and healthcare providers may not diagnose the disease in its early stages.

Reimbursement issues can also play a significant role in restraining the development of the market as patients may not opt for the treatment, as they may not be able to pay for the treatment if it is not covered under any insurance or government policies.

Country-wise Insights

Why is the United States a Profitable Market for Providers of Muscle-invasive Bladder Cancer Therapeutics?

“High Demand for Minimally-Invasive Procedures and Increasing Clinical Trials for Development of Effective Cancer Drugs”

The U.S. dominated the global market in 2022, generating revenue of US$ 382.05 million.

Growing demand for minimally invasive procedures to treat bladder cancer and development of novel medications and treatments to enhance patient outcomes are the key driving factors.

• According to the American Cancer Society, in the United States, there are more than 82,000 new cases of bladder cancer in 2023.

Researchers have been studying the effect of many therapies including targeted and combination therapies for bladder cancer.

• As per the National Cancer Institute (2023), an early-phase clinical trial using durvalumab (Imfinzi) in combination with tremelimumab before surgery is being studied in patients with muscle-invasive bladder cancer.

How is Demand for Muscle-invasive Bladder Cancer Therapeutics Shaping Up in China?

“Government’s Favorable Policies Governing Early Cancer Diagnosis and Cure”

China accounted for 62.7% share of the East Asia market in 2022.

Bladder cancer mainly affects the older population over the age of 55 years. China’s population is aging rapidly and so are cancer incidence and mortality.

• As per the NIH, bladder cancer statistics projected more than 91,000 new cancer cases in China in 2022.

• In 2019, China had the highest incidence of bladder cancer among 204 countries globally, as per the 2019 Global Burden of Disease (GBD) and GLOBOCAN databases.

China's ageing population together with rising healthcare costs and increasing cancer incidence is driving the regional market growth. Entry of international pharma companies into the Chinese market, the government's supportive policies, and the growing number of clinical trials for MIBC treatments are set to provide lucrative opportunities to market players.

What is the Demand Outlook for Muscle-invasive Bladder Cancer Therapeutics in Germany?

“Increasing Awareness about Early Cancer Detection and Treatment”

Germany dominated the European region with 23.1% market share in 2022.

Germany is one of the leading countries in terms of average patient enrollment for MIBC clinical trials in 2022. The rising incidence of muscle-invasive bladder cancer and the demand for efficient therapies is anticipated to expand the market in Germany.

• As per an article published in NIH-2022, titled “Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019,” a population-based study was conducted to understand the trends in treatment among MIBC-diagnosed patients in Germany. The study showed that 3 out of 4 patients received primary treatment and the number of patients who did not receive treatment remained low.

The growing public awareness regarding the importance of early cancer detection and treatment and increasing research and development efforts in the area are factors that will fuel market expansion.

Category-wise Insights

Therapies for Which Cancer Grade Account for a Dominant Market Share?

“Need for Prevention of High-grade Cancer Boosting Adoption of Low-grade Muscle-invasive Bladder Cancer Therapeutics”

Low-grade bladder cancer led the global market contributing US$ 620.7 million in 2022.

Due to the rising frequency of low-grade bladder cancer, demand for muscular-invasive bladder cancer therapeutics has surged. One of the most common types of bladder cancer is low grade, and if left untreated, it is likely to progress to high-grade cancer. It is essential to diagnose and treat low-grade bladder cancer as soon as possible to prevent its spread. Muscle-invasive bladder cancer treatments that aim to treat low-grade and early-stage bladder cancer without invasive surgical procedures have therefore become more necessary.

Which Drug Type is Extensively Used in the Treatment of Muscle-invasive Bladder Cancer?

“Improved Patient Outcomes Associated with Chemotherapy Drugs”

The chemotherapy drugs segment dominated the market in 2022; however, demand for immunotherapy is set to rise at a CAGR of 16.4% through 2033.

Chemotherapy is largely adopted as an effective treatment option for cancer because it is a systemic treatment that can target cancer cells throughout the body. In muscle-invasive bladder cancer, cancer cells spread beyond the bladder lining and may invade nearby tissues or lymph nodes.

Chemotherapy helps shrink the tumor and slow down the progression of the cancer, and it can also be used before or after surgery to improve outcomes. This increased adoption of chemotherapy as a treatment option for muscle-invasive bladder cancer is likely to contribute to market growth, as more patients will be seeking chemotherapy treatment and there will be a growing demand for chemotherapy drugs.

Competition Landscape

The global market is highly driven by the active participation of leading players in research and development as well as increasing clinical trials to develop novel drugs.

• In February 2021, Roche announced the initiation of a Phase III clinical trial for its antibody-drug conjugate, enfortumab vedotin, in MIBC patients who have previously received platinum-containing chemotherapy and immunotherapy.
• In March 2020, Astellas Pharma announced the initiation of a Phase III clinical trial for its FGFR inhibitor, rogaratinib, in MIBC patients who have FGFR genetic alterations.

The team at Persistence Market Research has tracked recent developments related to companies in the muscle-invasive bladder cancer therapeutics market, which are available in the full report.

Muscle-invasive Bladder Cancer Therapeutics Industry Report Scope

Muscle-invasive Bladder Cancer Therapeutics Industry Segments

Cancer Grade:

• Low-grade Bladder Cancer
• High-grade Bladder Cancer

Drug Type:

• Immunotherapy
  • Bacillus Calmette-Guerin
  • Avelumab
  • Nivolumab
  • Pembrolizumab
  • Others
• Chemotherapy
  • Mitomycin C
  • Docetaxel
  • Paclitaxel
  • Cisplatin
  • Others
• Targeted Therapy
  • Erdafitinib
  • Enfortumab Vedotin-ejfv
  • Sacituzumab Govitecan
  • Others

Distribution Channel:

• Hospitals Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

To know more about delivery timeline for this report Contact Sales